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Distinct patterns of gained chromosomes in high hyperdiploid acute lymphoblastic leukemia with t(1;19)(q23;p13), t(9;22)(q34;q22) or MLL rearrangements High hyperdiploidy (HeH; 51-67 chromosomes) is seen in B25% of childhood and B7% of adult acute lymphoblastic leukemia (ALL). 1, 2 Cases display a massive gain of chromosomes that results in a characteristic pattern of trisomies X, 4, 6, 10, 14, 17, and 18 and tetrasomy 21. In rare instances (2-3% of HeH cases), childhood ALL with a high hyperdiploid chromosome number also harbor t(1;19)(q23;p13)/TCF3-PBX1 fusion, t(9;22)(q34;q11)/ BCR-ABL1 fusion or 11q23/MLL rearrangements (t-HeH). 3 In adult ALL, similar frequencies of HeH and t(1;19) [t(1;19)/der(19)t(1;19)-HeH] and 11q23/MLL [MLL-HeH] are seen, whereas HeH together with t(9;22) [t(9;22)-HeH] is more common; t(9;22) is found in B30% of cases with 51-67 chromosomes. 2 When classifying ALL by genetics, t-HeH cases are usually grouped according to the translocation. Such cases appear to have a worse prognosis than 'classic' HeH (c-HeH) in both children and adults, although this is based on relatively small patient series. 2, 4 It has been reported that patients with t(9;22)-HeH have a better outcome than those with t(9;22) in a diploid context; however, they still display a shorter event-free survival than c-HeH patients. 2, [5] [6] [7] In this study, we have utilized single nucleotide polymorphism (SNP) array analysis to investigate nine t(9;22)-HeH and two MLL-HeH ALL patients (Supplementary Table 1 ). SNP array data from four previously published cases were also included; 8 original case numbers 5, 6, 10 [t(9;22)-HeH] and 11 [t(4;11)(q21;q23)-HeH]. DNA was extracted according to standard methods from bone marrow samples acquired at diagnosis, and SNP array analyses were performed using the Human Omni-1 Quad BeadChip platform (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. Data analyses were done using the GenomeStudio v2011.1 software with Illumina Genome Viewer 1.9.0 (Illumina). In addition, data from ALL cases reported in the literature with 51-67 chromosomes and concurrent (a) t(9;22)(q34;q11), (b) t(4;11)(q21;q23) or t(11;19)(q23;p13), or (c) t(1;19)(q23;p13)/ der(19)t(1;19) were extracted from the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer, 3 and data from adult ALL cases with 51-65 chromosomes and one of the above-mentioned rearrangements were extracted from the karyotype database held by the Leukemia Research Cytogenetics Group (LRCG), Newcastle University, UK.
2 Specific gains and modal numbers were ascertained from G-banded karyotypes, as published or reported by clinical laboratories. Cases with a range of modal numbers were classified as having the highest modal number in the range.
The t(9;22)-HeH cases had a median modal number of 55 both by SNP array analysis and in the cytogenetic review, which included 80 t(9;22)-HeH cases from the literature and 44 cases from the LRCG data base, similar to c-HeH (Figure 1a) . 9 In all, 4 (33%) of the 12 cases investigated by SNP array analysis harbored whole-chromosome uniparental isodisomies and 8 of 9 tetrasomies had duplicated both homologs (Supplementary Table 1 ), in line with c-HeH in general. 9 In c-HeH, this pattern has been interpreted as the majority of cases arising in one aberrant mitosis, either directly from diploidy or via a tetraploid state. 10 Taken together, the available data suggest that the HeH in t(9;22)-HeH cases may occur by a similar mechanism. However, case 2, which had a 3:1 tetrasomy 14 indicating sequential gains of that chromosome, and case 9, which had subclonality indicating sequential gains of several chromosomes, may be exceptions. In total, 10% of the t(9;22)-HeH cases in the cytogenetic review and 2/12 cases analyzed by SNP array had a stemline with t(9;22) only. Case 2 displayed the opposite pattern, that is, a stemline with HeH only by G-banding; no such case has been previously reported in the literature. Gain of an extra derivative chromosome 22 was present in 75% of the cases. These findings indicate that the translocation usually arises first, followed by the hyperdiploidy. Another fact that points in the same direction is the pattern of the gains, which displays both similarities and differences compared with the gains in c-HeH. For example, chromosomes X, 4, 6, 14 and 21 were gained in the majority of cases (Figure 2a ), similar to c-HeH. 9 However, trisomies 10, 17 and 18 were much rarer; þ 17 was seen in only 1 (8.3%) of the cases analyzed with SNP array compared with B80% of c-HeH analyzed with the same method (Po0.001; two-tailed Fisher's exact probability test). 9 Trisomy 2, on the other hand, was more frequent, being present in 58% of the t(9;22)-HeH cases compared with 2.7% of c-HeH (Po0.001), and trisomy 19 was seen in 4 (33%) of the 12 cases, but not in a single case of the 74 c-HeH cases previously investigated (Po0.001). 9 This suggests that different chromosomal gains may give a selective advantage in cases that harbor a t(9;22), that is, þ 2 and þ 19 may be leukemogenic in a high hyperdiploid background only if the cell also carries a t(9;22), whereas þ 17 may not.
Few MLL-HeH cases could be evaluated; 3 with SNP array analysis and 11 in the cytogenetic review, of which 10 cases from the literature and 1 from the LRCG database. All cases had modal numbers of 51-53 ( Figure 1b ; Supplementary Table 1), which differs from the pattern seen in c-HeH. 9 This indicates that the underlying mechanism of the gains in MLL-HeH differs from c-HeH. Furthermore, the pattern of chromosomal gains appeared Figure 2b) ; only chromosomes X, 4, 6, 13 and 21 were gained in 450% of the cases by either SNP array or G-banding analyses. Three (27%) of the cases with cytogenetic data had a stemline with the MLL rearrangement only, indicating that the HeH was a secondary chromosomal event. Taken together, the limited data suggest that the chromosomal gains seen in MLL-HeH cases are different from the high hyperdiploid pattern seen in the c-HeH group, both regarding the mechanism of formation and their pathogenetic outcome.
The survey of G-banding data from t(1;19)/der(19)t(1;19)-HeH included 28 published cases and 14 cases from the LRCG database, showing a median modal number of 56 and a distribution of modal numbers similar to the c-HeH subgroup (Figure 1c) , 9 which may indicate a similar mechanism of formation. Also, the pattern of gained chromosomes was the same as in c-HeH (Figure 2c ). 9 Notably, 11 (26%) of the 42 cases harbored a stemline with HeH only whereas no case displayed the opposite pattern, suggesting that the chromosomal gains may occur before the translocation. Thus, this subtype may be more similar to c-HeH. Interestingly, it has been reported that the TCF3/PBX1 fusion gene frequently is not expressed and that no TCF3 rearrangements are seen by interphase fluorescence in situ hybridization (FISH) analysis of t(1;19)/der(19)t(1;19)-HeH cases. 11, 12 Whereas the former may be due to different breakpoints within the TCF3 and PBX1 genes, prohibiting detection with standard primers and probes, the latter indicates that different genes are involved. In fact, 7 of the 14 LRCG database cases had been screened for TCF3 involvement by reverse transcription-PCR or FISH; only 1 (14%) showed rearrangement of this gene. 12 Furthermore, the majority of t(1;19)/der(19)t(1;19)-HeH cases harbored an unbalanced der(19)t(1;19); only 18% had the balanced form of the rearrangement. This may be compared with 40% of TCF3/PBX1-positive cases in general having a balanced t(1;19) (P ¼ 0.00580; two-tailed Fisher's exact probability test). 3 Previous studies have shown that the majority of cases with t(1;19)/der(19)t(1;19) without TCF3 involvement harbor the unbalanced form of the rearrangement, 11, 12 further supporting the hypothesis that the t(1;19)/der(19)t(1;19) seen in t-HeH cases may in fact result in a different fusion gene.
A total of 23 intrachromosomal aberrations were detected in the 12 cases analyzed by SNP array as a part of this study (Supplementary Table 2 ). Microdeletions observed included the well-known target genes IKZF1, CDKN2A, PAX5, ETV6 and IKZF3, which are frequently deleted in ALL. 8, 13 However, IKZF1 deletion was seen in only 1 (8.3%) of the 12 t(9;22)-HeH cases. This is substantially lower than the frequency (65-85%) in t(9;22)-positive cases in general. 14, 15 As losses of IKZF1 are associated with an inferior prognosis in childhood and adult ALL, 14, 15 this may be one explanation for the reported better outcome of t(9;22)-HeH patients compared with cases with t(9;22) within a diploid background. 2, [5] [6] [7] ALL with concurrent t(9;22), MLL rearrangement or t(1;19)/ der(19)t(1;19) and HeH is rare, and additional studies are needed to determine definitely the underlying mechanism and clinical features associated with these cases before any recommendations on changes in classification or treatment stratification can be given. Nevertheless, this study has indicated some key characteristics of t(9;22)-HeH, MLL-HeH and t(1;19)/der(19)t(1;19)-HeH. In summary, our results indicate that in t(9;22)-HeH and MLL-HeH cases, the translocation is the primary genetic event.
As the HeH arises after the translocation and is at least partly different in these cases from the one seen in the c-HeH subgroup, t(9;22)-HeH and MLL-HeH cases are correctly classified as translocation-positive and not as a part of the c-HeH subgroup. However, for t(1;19)/der(19)t(1;19)-HeH cases, the opposite appears to be true; the chromosomal gains are the primary genetic event and the translocation arises later. Considering that several investigators have also reported the absence of TCF3/PBX1 fusion gene, 11, 12 Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral cytopenias and increased propensity for progression to acute myeloid leukemia. 1 p38 mitogen-activated protein kinase (MAPK) belongs to a family of widely expressed serine-threonine kinases, 2 which include four isoenzymes (a,b,g and d) encoded by different genes with distinct tissue expression patterns. In bone marrow biopsy sections from patients with lower-risk MDS, immunohistochemical staining revealed constitutive activation of p38a MAPK in bone marrow precursors irrespective of morphologic subtype. 3, 4 Increased phosphorylation of p38a MAPK correlated with interleukin (IL)-1b expression level and cleaved caspase-3, implicating the signaling pathway in the apoptotic response in MDS. 5 We investigated the safety and tolerability, as well as hematologic response and pharmacodynamics, of SCIO-469 (indole-5-carboxamide), a potent selective adenosine triphosphate-competitive inhibitor of p38a MAPK. 5, 6 We conducted the phase I/II randomized, open-label, multicenter, modified parallel dose escalation study in patients with low-and intermediate-1-risk MDS classified according to International Prognostic Scoring System (IPSS) 7 who did not respond to prior treatment with a recombinant erythropoietin. The protocol was approved by the Institutional Review Board at each participating institution, and all patients provided informed written consent.
Between April 2005 and May 2006, we enrolled 62 patients at 10 centers in the United States (Table 1) . Eligible patients had a diagnosis of MDS of at least 8-week duration (see additional inclusion and exclusion criteria at ClinicalTrials.gov, identifier NCT00113893). Patients received pretrial screening within 35 days of study entry and clinical laboratory assessments every 2 weeks through week 16, every 4 weeks after week 16 and every 8 weeks after week 52. Bone marrow aspiration and biopsy were performed every 8 weeks through week 16, every 8 weeks through week 52 and every 6 months after week 52. Four dose levels of oral SCIO-469 were studied: 30 mg (90 mg per day; 15 patients), 60 mg (180 mg per day; 15 patients), 90 mg (270 mg per day; 15 patients) and 120 mg (360 mg per day; 17 patients) three times daily. Initially, patients were randomly assigned to receive either 90 mg per day or 180 mg per day. Randomization to the next higher-dose group was deferred until a successful first interim safety analysis was completed. The expansion to the 360 mg per day group was contingent on the results of a second interim safety analysis conducted after 15 subjects in each of the first three dose levels had been enrolled. Hematologic responses were assessed after 16 weeks of treatment according to modified International Working Group criteria. 8 Responders and those experiencing clinical benefit in the opinion of the investigator could continue the assigned treatment for up to 36 additional weeks. Similar criteria were applied at week 52 and week 78 to determine eligibility to continue treatment for an additional 26 weeks. Maximum treatment duration was 104 weeks.
Forty-seven patients completed treatment through week 16. Among the 15 patients who terminated the study prematurely, three withdrew because of a non-hematologic serious adverse event (AE), with two considered drug related (exacerbation of congestive heart failure at 180 mg per day and atrial fibrillation at 360 mg per day) and one non-drug related (grade 2 asthenia at 360 mg per day). Eight patients withdrew prematurely because of an AE (graded according to National Cancer Institute common toxicity criteria version 3.0 9 ), with two considered severe and drug related (grade 4 neutropenia at 270 mg per day and grade 3 elevation of alanine aminotransferase (ALT) at 360 mg per day). The remaining AEs included abdominal pain, malignant melanoma and colon cancer, all considered unrelated, as well as rash (360 mg per day), duodenal ulcer (360 mg per day) and elevated ALT (360 mg per day), which were considered possibly drug related. Four patients discontinued therapy prematurely for other reasons. Twelve patients qualified for and elected to continue treatment beyond week 16, with five completing treatment through week 52 but seven withdrawing before week 52 because of disease progression (two patients) or reasons unrelated to drug tolerance (five patients). There were no study-related deaths.
Most AEs were mild or moderate in severity, unrelated to study drug and easily managed. We documented 64 AEs of grade 3 severity or higher in 25 patients, with 19 events in 10 patients considered drug related. Two patients experienced drug-related grade 3 and 4 neutropenia (270 mg per day, 360 mg per day). Severe nonhematologic events thought to be drug-related were rash, abdominal pain and jaundice, gastric ulcer, chest tightness, angina, and atrial fibrillation. Twenty-seven of 56 evaluable patients experienced QT/QTc prolongation at one or more post-baseline assessments. None of the QT/QTc interval increases were associated with AEs.
Hematological improvement and bone marrow response had a minimum duration requirement of 8 weeks. Patients who achieved response at week 16 could continue on the same dose of SCIO-469 with periodic observation for disease progression, AEs or non-response. Eighteen of 62 patients (29%) experienced Accepted article preview online 11 September 2012; advance online publication, 2 October 2012
